AR036098A1 - Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos - Google Patents

Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos

Info

Publication number
AR036098A1
AR036098A1 ARP020102303A ARP020102303A AR036098A1 AR 036098 A1 AR036098 A1 AR 036098A1 AR P020102303 A ARP020102303 A AR P020102303A AR P020102303 A ARP020102303 A AR P020102303A AR 036098 A1 AR036098 A1 AR 036098A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
heterocyclyl
cycloalkyl
preparation
Prior art date
Application number
ARP020102303A
Other languages
English (en)
Inventor
Helmut Heinrich Buschmann
Englberger Werner Guenter Dr
Tieno Germann
Michael Haurand
Hennies Hagen-Heinrich Dr
Corinna Maul
Sundermann Bernd Dr
Joerg Holenz
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR036098A1 publication Critical patent/AR036098A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)

Abstract

Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos de la fórmula general (1), en forma de sus racematos, sus estereoisómeros puros, particularmente enantiómeros o diasteréomeros o en forma de mezcla de sus estereoisómeros, particularmente de los enantiómeros y diasteréomeros, en cualquier proporción; en la forma representada o en la forma de sus ácidos o sus bases o en forma de sus sales, particularmente sales fisiológicamente tolerables, con particular preferencia en forma de sus clorhidratos, o en forma de sus solvatos, particularmente hidratos; en la cual: R1 y R2 representan independientemente entre sí H, alquilo C1-8, cicloalquilo C3-10, (alquil C1-12)-cicloalquilo C3-10, arilo, (alquil C1-12)-arilo, heterociclilo, (alquil C1-12)-heterociclilo o NH-C(=O)-arilo, siendo al menos uno de los radicales R1 y R2 distinto de H, o R1 y R2 representan conjuntamente -(CR4R5)m-(CR6R7)n-Y-(CR8R9)p-(CR10R11)q- siendo respectivamente m, n, p y q alguno de los números 0, 1, 2, 3, 4 ó 5, con la condición que m + n es 1, y que p + q es 1, o representan -CH2-CH2-C(arilo)=CH-CH2-; R3 representa H, SO2R12 o COR13; R4, R5, R6, R7, R8, R9, R10 y R11 representan independientemente entre sí H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo o C(=O)R14; Y representa CR15R16, NR17 u O; R12 y R13 representan independientemente entre sí alquilo C1-10, cicloalquilo C3-10, (alquil C1-6)-cicloalquilo C3-10, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo o NR18R19; R14 representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo u OR20; R15 y R16 representan independientemente entre sí H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo, o C(=O)R21; R17 representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo o C(=O)R22; R18 y R19 representan independientemente entre sí representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, o (alquil C1-6)-heterociclilo; R20 representa representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, o (alquil C1-6)-heterociclilo; R21 representa representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo u OR23; R22 representa representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo u OR24; y R23 y R24 representan independientemente entre sí representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, o (alquil C1-6)-heterociclilo; procedimientos para su preparación, su uso para la preparación de medicamentos y medicamentos que contienen estos compuestos. Estos compuestos son adecuados para la terapia del dolor y eventualmente para el caso de dolores neuropáticos y crónicos.
ARP020102303A 2001-06-25 2002-06-19 Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos AR036098A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10130020A DE10130020A1 (de) 2001-06-25 2001-06-25 Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate

Publications (1)

Publication Number Publication Date
AR036098A1 true AR036098A1 (es) 2004-08-11

Family

ID=7689008

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102303A AR036098A1 (es) 2001-06-25 2002-06-19 Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos

Country Status (30)

Country Link
US (2) US8048890B2 (es)
EP (1) EP1401841B1 (es)
JP (1) JP4410554B2 (es)
KR (1) KR100917112B1 (es)
CN (1) CN1315840C (es)
AR (1) AR036098A1 (es)
AT (1) ATE302782T1 (es)
AU (1) AU2002310768B2 (es)
BR (1) BR0211053A (es)
CA (1) CA2451859C (es)
CO (1) CO5540301A2 (es)
CZ (1) CZ20033432A3 (es)
DE (2) DE10130020A1 (es)
DK (1) DK1401841T3 (es)
EC (1) ECSP034924A (es)
ES (1) ES2245402T3 (es)
HK (1) HK1064669A1 (es)
HU (1) HU228774B1 (es)
IL (2) IL159544A0 (es)
MX (1) MXPA03012013A (es)
NO (1) NO332217B1 (es)
NZ (1) NZ530689A (es)
PE (1) PE20030146A1 (es)
PL (1) PL214290B1 (es)
PT (1) PT1401841E (es)
RU (1) RU2296128C2 (es)
SI (1) SI1401841T1 (es)
SK (1) SK287390B6 (es)
WO (1) WO2003000699A1 (es)
ZA (1) ZA200400489B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
NZ537521A (en) * 2002-08-14 2007-05-31 Pharmacia & Upjohn Co Llc Use of reboxetine for the treatment of hot flashes
DE102004023635A1 (de) * 2004-05-10 2006-04-13 Grünenthal GmbH Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102005016170A1 (de) * 2005-04-07 2006-10-12 Grünenthal GmbH 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044814A1 (de) * 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005023784A1 (de) * 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044813A1 (de) * 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
US8653068B2 (en) 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US8614324B2 (en) * 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US9340558B2 (en) 2007-11-02 2016-05-17 Pain Therapeutics Inc. Filamin a binding anti-inflammatory and analgesic
US8580808B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutic, Inc. Filamin A-binding anti-inflammatory analgesic
US20100279996A1 (en) * 2009-05-04 2010-11-04 Lindsay Burns Barbier Novel analgesic that binds filamin a
WO2010051476A1 (en) * 2008-10-31 2010-05-06 Pain Therapeutics, Inc. Filamin a-binding anti-inflammatory analgesic
BRPI1007350B8 (pt) * 2009-01-26 2021-05-25 Israel Institute For Biological Res compostos espiro heterocíclicos bicíclicos
US8580809B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
EP2872899B1 (en) 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient
DK2882428T3 (en) 2012-07-13 2019-04-15 Pain Therapeutics Inc PROCEDURE TO INHIBIT TAU PHOSPHORIZATION
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
HUE051642T2 (hu) 2016-01-13 2021-03-01 Gruenenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4,5]-dekán származékok
AU2017206910B2 (en) 2016-01-13 2020-07-16 Grünenthal GmbH 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2018008644A (es) 2016-01-13 2018-11-19 Gruenenthal Gmbh Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espir o-[4.5]-decano.
CN108699005B (zh) 2016-01-13 2021-11-30 格吕伦塔尔有限公司 3-(羧基乙基)-8-氨基-2-氧代-1，3-氮杂-螺-[4.5]-癸烷衍生物
EP3402781B1 (en) 2016-01-13 2020-03-04 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
KR102168543B1 (ko) * 2017-04-12 2020-10-21 일동제약(주) 핵 수용체의 효능제인 아이속사졸 유도체 및 이의 용도
CN109793713B (zh) * 2019-03-26 2021-05-28 李世系 一种用于麻醉的短效催眠镇静的药物组合物及其注射剂制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127065C (es) * 1964-04-22
GB1227365A (es) * 1968-07-29 1971-04-07
JPH02164882A (ja) * 1988-12-20 1990-06-25 Yamanouchi Pharmaceut Co Ltd スピロ化合物及びその中間体
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5739336A (en) * 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
DE19528472A1 (de) * 1995-08-03 1997-02-06 Boehringer Ingelheim Kg Neues Verfahren zur Herstellung von Norbenzomorphan einer Zwischenstufe bei Herstellung von pharmazeutisch wertvollen Benzomorphanderivaten, insbesondere von (-)-(1R,5S,S"R)-3'-Hydroxy-2-(2-methoxypropyl-)-5,9,9-trimethyl-6,7 benzomorphan
JPH11512723A (ja) * 1995-09-29 1999-11-02 イーライ リリー アンド カンパニー フィブリノゲン依存血小板凝集抑制物質としてのスピロ化合物
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
EP0888344A1 (en) * 1996-03-15 1999-01-07 The Du Pont Merck Pharmaceutical Company Spirocycle integrin inhibitors
AU6780398A (en) * 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
AU1776100A (en) 1998-11-18 2000-06-05 Basf Aktiengesellschaft Method of producing 2-alkyl-3-(4,5-dihydroisoxazole-3-yl)-halobenzenes
KR20030000243A (ko) 2001-06-22 2003-01-06 이 석 민 동물사료 제조방법 및 그에 적합한 기밀 플라스틱백발효용기
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate

Also Published As

Publication number Publication date
PL367748A1 (en) 2005-03-07
DE10130020A1 (de) 2003-12-04
ECSP034924A (es) 2004-02-26
IL159544A (en) 2009-05-04
ATE302782T1 (de) 2005-09-15
PE20030146A1 (es) 2003-03-15
ZA200400489B (en) 2004-10-14
JP2004536095A (ja) 2004-12-02
MXPA03012013A (es) 2004-03-26
US20040192916A1 (en) 2004-09-30
CN1315840C (zh) 2007-05-16
RU2004100823A (ru) 2005-06-20
WO2003000699A8 (de) 2003-11-20
HUP0400810A2 (hu) 2004-07-28
SK15702003A3 (sk) 2004-07-07
CA2451859A1 (en) 2003-01-03
NO332217B1 (no) 2012-07-30
KR100917112B1 (ko) 2009-09-11
US8557796B2 (en) 2013-10-15
NO20035730L (no) 2004-02-19
NO20035730D0 (no) 2003-12-19
AU2002310768B2 (en) 2007-01-11
CZ20033432A3 (cs) 2004-05-12
SI1401841T1 (sl) 2006-02-28
EP1401841B1 (de) 2005-08-24
JP4410554B2 (ja) 2010-02-03
US20110224172A1 (en) 2011-09-15
DE50204037D1 (de) 2005-09-29
CO5540301A2 (es) 2005-07-29
EP1401841A1 (de) 2004-03-31
HUP0400810A3 (en) 2007-11-28
HU228774B1 (en) 2013-05-28
CN1547584A (zh) 2004-11-17
NZ530689A (en) 2005-07-29
CA2451859C (en) 2011-06-14
US8048890B2 (en) 2011-11-01
PL214290B1 (pl) 2013-07-31
HK1064669A1 (en) 2005-02-04
KR20040008226A (ko) 2004-01-28
BR0211053A (pt) 2004-07-20
DK1401841T3 (da) 2005-09-19
SK287390B6 (sk) 2010-08-09
RU2296128C2 (ru) 2007-03-27
PT1401841E (pt) 2005-11-30
ES2245402T3 (es) 2006-01-01
WO2003000699A1 (de) 2003-01-03
IL159544A0 (en) 2004-06-01

Similar Documents

Publication Publication Date Title
AR036098A1 (es) Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR057383A1 (es) Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR077553A2 (es) Compuestos de triazolo [4,5-d] pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacion de dichos compuestos
AR082994A1 (es) Derivados de pirazina como bloqueadores del canal epitelial de sodio
AR034244A1 (es) Derivados de 4-aminopiperidina y su uso como medicamento
AR054809A1 (es) Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
NO20050065L (no) Kjemiske forbindelser
HUP0301671A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
AR017217A1 (es) Compuestos antiarritmicos de bispidina, formulacion farmaceutica, uso de los mismos para preparar medicamentos, proceso para preparar dichos compuestos,compuestos intermediarios, y proceso para prepararlos
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
ES2369837T3 (es) Compuestos triheterocíclicos como antagonistas de receptor cfr.
AR039689A1 (es) Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR035235A1 (es) Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento
BG101402A (en) Apoliprotein-b synthesis inhibitors
DE69210875T2 (de) Piperidinderivate, Verfahren zu deren Herstellung und deren therapeutische Anwendung
HUP0303801A2 (hu) Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DK538886A (da) 3-oxadiazol- og 3-carbonsyre-beta-carbolinderivater, deres fremstilling og deres anvendelse som laegemiddel
AR041895A1 (es) Derivados de 4 (fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales
ZA899356B (en) Novel compounds
AR042887A1 (es) Derivados de diarilmetiden piperidina preparaciones y usos de los mismos
AR061458A1 (es) Derivados de aril y heteroaril-etil-acilguanidina, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure